---
schema_version: "secwatch.filing_event.v1"
accession: "0002023658-25-000006"
form_type: "8-K"
ticker: "BCAX"
cik: "0002023658"
company_name: "Bicara Therapeutics Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:24:22.104868+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bicara Therapeutics reports Q4 net loss $21M, cash $489.7M; pivotal Phase 2/3 trial dosing started

## Summary
- Net loss $21.0M in Q4 2024, $68.0M full year; vs $12.4M and $52.0M in 2023.
- Cash and equivalents $489.7M as of Dec 31, 2024, up from $230.4M; funds operations into first half 2029.
- First patients dosed in February 2025 in FORTIFI-HN01, pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC.
- Updated Phase 1/1b data for ficerafusp alfa in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting.
- Three abstracts on ficerafusp alfa accepted for AACR 2025, including monotherapy in cSCC and preclinical lung cancer data.

## SEC filing metadata
- accession: 0002023658-25-000006
- form_type: 8-K
- ticker: BCAX
- cik: 0002023658
- company_name: Bicara Therapeutics Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023658/000202365825000006/0002023658-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023658/000202365825000006/bcax-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002023658-25-000006
- JSON: https://secwatch.observer/filing/0002023658-25-000006.json
- Plain text: https://secwatch.observer/filing/0002023658-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.